Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14524692 | 0.91 | SMN1; SMN2 (0.47) | PPARADRD2DRD4DRD3SMN1; SMN2 | |
| SCHEMBL16472055 | 0.89 | PPARA (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL322285 | 0.83 | PPARA (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21414840 | 0.83 | PPARA (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12868339 | 0.83 | DRD2 (0.52) | PPARADRD2DRD4DRD3NPC1 | |
| SCHEMBL1343630 | 0.81 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2565153 | 0.81 | TDP1 (0.55) | MAPTAPPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11988222 | 0.81 | LTA4H (0.55) | DRD2DRD4DRD3SMN1; SMN2 | |
| SCHEMBL10202971 | 0.81 | CYP1A2 (0.50) | DRD2DRD4DRD3NPC1RAB9A | |
| SCHEMBL12384893 | 0.81 | KDM4E (0.54) | MAPTAPPNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477497-A2 | SYNERGISTIC FUNGICIDAL COMBINATIONS CONTAINING A DITHIINO-TETRACARBOXAMIDE FUNGICIDE | Bayer CropScience AG (DE) | 2012-07-25 | — | — | EP | claimed |
| EP-2445348-A1 | COMBINATIONS OF FUNGICIDALLY ACTIVE YEAST AND FUNGICIDES | Bayer Cropscience AG (DE) | 2012-05-02 | — | — | EP | claimed |
| WO-2011029551-A2 | ACTIVE COMPOUND COMBINATIONS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2011-03-17 | — | — | WO | claimed |
| WO-2010149369-A1 | COMBINATIONS OF FUNGICIDALLY ACTIVE YEAST AND FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2010-12-29 | — | — | WO | claimed |
| WO-2010025870-A1 | SYNERGISTIC COMBINATIONS OF THIADIAZOL CARBONIC ACID DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | claimed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2023-01-24 | — | — | US | disclosed |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2022-01-04 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| WO-2006122952-A1 | 2-PYRIDINYLCYCLOALKYLBENZAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | BAYER CROPSCIENCE SA (FR) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006122955-A1 | NEW 2-PYRIDINYLCYCLOALKYLCARBOXAMIDE DERIVATIVES AS FUNGICIDES. | BAYER CROPSCIENCE SA (FR) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006117356-A1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117358-A1 | NEW HETEROCYCLYLETHYLAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006108791-A2 | HETEROCYCLYLETHYLHETEROCYCLYLCARBOXAMIDE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE SA (FR) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108792-A1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | CA12 3573/4885CA1 4238/4885CA2 4222/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | CA12 3573/4885CA1 4238/4885CA2 4222/4885 |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | CA12 4647/4885CA1 4870/4885CA2 4606/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | CA12 4647/4885CA1 4870/4885CA2 4606/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | CA12 4647/4885CA1 4870/4885CA2 4606/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | CA12 1512/4885CA1 1652/4885CA2 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.